Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -299.71% | -125.97% | -44.28% | 23.73% | 42.43% |
| Total Depreciation and Amortization | -47.06% | 4.55% | -9.93% | -21.05% | -29.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,113.91% | 37.82% | -9.83% | -30.88% | -36.75% |
| Change in Net Operating Assets | 144.82% | 91.35% | 44.00% | -1,288.85% | -1,381.19% |
| Cash from Operations | -12.54% | -101.58% | -34.11% | 6.02% | 20.34% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -97.98% | -59.20% | -38.58% |
| Cash from Investing | -- | -100.46% | -98.19% | -59.45% | -38.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.81% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 100.00% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -136.91% | -22.78% | 57.97% | 1,175.15% | 660.29% |